Core 10 - Thomas Gunter

Core 10 - Thomas Gunter

Manganese Health Research Program: Phase 2, Core 10

Research Core Project Number:  
Research Core Project: Mechanisms of Manganese-Induced Damage at the Cell and Mitochondrial Level
Core Principal Investigator (CPI): Dr Thomas Gunter
   


 

Dept. of Biochemistry and Biophysics; Univ. of Rochester Medical School
601 Elmwood Ave. : P.O. Box 712 ; Univ. of Rochester Medical School ;    
Rochester ,NY 14642 : thomas_gunter@urmc.rochester.edu : (585-275-3129)

   

 

Key Collaborators:

 

Dr. Karlene Gunter
Dept. of Biochemistry and Biophysics; Univ. of Rochester Medical School     
601 Elmwood Ave. : P.O. Box 712; Univ. of Rochester Medical School ;  
Rochester , NY 14642 :karlene_gunter@urmc.rochester.edu : (585-275-3753)

 

Dr. Michael Aschner
Dept. of Pediatrics; Vanderbilt Univ. Medical Ccenter
1162 21 st Ave. South ; B-3307, Medical Center North;  
Vanderbilt Univ. Medical Center . michael.aschner@Vanderbilt.edu (615-322-8024)

Project Objectives:

  1. To determine whether Mn2+ interferes with Ca2+ activation of pyruvate dehydrogenase (PDH), isocitrate dehydrogenase (ICDH) a-ketoglutarate dehydrogenase (aKGDH) or the F1F0 ATP synthase and decreases the rate of Ca2+-stimulated ATP production using oxidation rate experiments.
  2. To determine whether Mn2+ can inhibit mitochondrial ETC complex 1 using oxidation rate experiments.
  3. To characterize the effect of Mn2+ on ATP production, ROS production, and cell death in neuronal cell lines in the presence of factors known to produce signs of PSN in animals.

Project Description:

Earlier work in our laboratory has used x-ray spectroscopic techniques to show that no observable manganese3+ (Mn3+) is produced by oxidation of Mn2+ in brain mitochondria, neuron-like cells or astrocytes.  This has led us to hypothesize that the proximal cause or causes of Mn toxicity are either transport of Mn3+ into the target tissue or damage by Mn2+.  As is discussed in the Background, we believe that possible damage by Mn2+ is likely to be particularly important in explaining how Mn can act as a risk factor in Parkinsonism (PSM).  Mn2+ is known to bind to all Ca2+ binding sites with an affinity as strong as Ca2+’s or stronger (see Table 1).  In mitochondria the rate of ATP production can be increased by a factor of up to three by binding of Ca2+ to a set of dehydrogenases associated with the Krebs or TCA cycle and to the mitochondrial ATP synthase1-3.  Mn2+ binding to these sites of Ca2+ activation of ATP production could inhibit the activation and greatly decrease the ATP that can be produced in the high energy requiring cells of the target tissue.  We show in the Preliminary Data that this does occur at a-ketoglutarate dehydrogenase (a KGDH). Since a decrease in metabolic energy production has been postulated as a possible cause of PSM4-7, Mn2+ in the substantia nigra pars compacta (SNpc) and striatum, the target tissues for PSM, could be a factor in the development of PSM.

Furthermore, as is discussed in the Background, inhibitors of the mitochondrial electron transport chain (ETC) complex I show a particularly close relationship to the development of PSM, and in some cases have been shown to induce signs and symptoms indistinguishable from those of idiopathic Parkinson’s disease in humans, rats, and mice8-11.  We present arguments which suggest that Mn2+ might also function as an inhibitor of complex I.  If it does function in this way, it is very likely that it contributes to the development of PSM.  We have therefore suggested and now hypothesize two ways in which Mn2+ could function to increase the risk of development of PSM: 1) by decreasing the supply of ATP in energy demanding cells, and 2) by functioning as a complex I inhibitor, a stress which has been closely connected to the development of PSM.  We propose 3 specific aims to test these hypotheses and to characterize the effects of Mn2+ on dopaminergic neurons and astrocytes under conditions related to those in which development of PSM occurs.

 

Project Status:

Project started:
Feb. 17, 2006
Scheduled completion date:
Feb. 17, 2008
Completed:  Jan. 31, 2009

Key research Accomplishments:

a) We developed a novel technique for identifying the sites of Mn2+ inhibition within the mitochondrial metabolic pathways and identified the F1F0 ATP synthase in liver and heart mitochondria and two completely different sites in brain mitochondria.  In brain mitochondria, Mn2+ inhibits either fumarase or complex II (succinate dehydrogenase) and also either the glutamate aspartate exchanger or aspartate aminotransferase.  We found no indication of inhibition at mitochondrial complex I.  We found that Mn nanoparticles, similar to forms of Mn seen in welding fumes, produce reactive oxygen species (ROS) and seem to kill cells by hyperactivation of lysosomes.  We are still working on the problem of Mn2+ transport via the RaM mechanism under alternative funding.  We have found that Mn2+ is not significantly transported via the Na+-dependent mitochondrial Ca2+ efflux mechanism.

Publications:

1. Gunter, T. E., C. E. Gavin, M. Aschner, and K.K. Gunter. Speciation of manganese in cells and mitochondria: A search for the proximal cause of manganese neurotoxicity. Neurotoxicology 27: 765 - 776, 2006.

2. Gunter, T.E., C. E. Gavin, and K. K. Gunter. The case for manganese interaction with mitochondria. Neurotoxicology 30: 727 - 729, 2009.

3. Gunter, T. E., and S. S. Sheu. Characteristics and possible functions of mitochondrial Ca2+ transport mechanisms. Biochem. Biophys. Acta (Bioenergetics) 1787: 1291 - 1308, 2009.

4. Van Winkle, B., K. Bentley, J. Malecki, K. K. Gunter, I. M. Evans, A. Elder, J. N. Finkelstein, G. Oberdorster, and T. E. Gunter. Nanoparticle (NP) uptake by type I alveolar epithelial cells and their oxidative stress response. Nanotoxicology 3: 307 - 318, 2009.

5. Gunter, T. E., B. Gerstner, T. Lester, A. P. Wojtovich, J. Malecki, S. G. Swarts, P. S. Brookes, C. E. Gavin, and K. K. Gunter. An analysis of the effects of Mn2+ on oxidative phosphorylation in liver, brain, and heart mitochondria using state 3 oxidation rate assays. Toxicol. and Appl. Pharmacol. 249: 65 - 75, 2010.

 

Presentations under the grants were:

1. Gunter, T. E., K.K. Gunter, and M. Aschner. Mn2+ interference with Ca2+ activation of ATP production by mitochondria: A novel hypothesis of Mn neurotoxicity.  22nd International Neurotoxicology Conference. Raleigh - Durham, NC; Sept. 11 - 14 2005.

2. Gunter, T. E., M. Aschner, J. Salter, and K. K. Gunter. Where does Mn2+ inhibit oxidative phosphorylation? 23rd International Neurotoxicology Conference. Little Rock AR, Sept 17 - 21, 2006.

3. Gunter, T. E., M. Aschner, T. Lester, J. Malecki, and K. Gunter.  Mn2+ inhibition of oxidative phosphorylation. 17th annual meeting of Setac Europe. Porto, Portugal, May 20 - 24, 2007.

4. Gunter, T. E., K. Gunter, B. Gerstner, T. Lester, J. Malecki, A. Wojtovich, and S. Swarts. Where does Mn2+ inhibit oxidative phosphorylation? or Mn2+ inhibition of the F1F0 ATP synthase.  The Manganese Health Research Program Showcase Conference; Londsdowne Resort; Washington, D.C. June 24 - 25, 2009.

5. Gunter, T. E., B. Gerstner, C. Gavin, and K. Gunter. Mn2+ inhibition of oxidative phosphorylation in liver, brain, and heart mitochondria. Society of Toxicology Meeting; Washington, D. C.; March 6 - 10, 2011.

Last updated: July, 2011


About cookies on our website

Following a revised EU directive on website cookies, each company based, or doing business, in the EU is required to notify users about the cookies used on their website.

Our site uses cookies to improve your experience of certain areas of the site and to allow the use of specific functionality like social media page sharing. You may delete and block all cookies from this site, but as a result parts of the site may not work as intended.

To find out more about what cookies are, which cookies we use on this website and how to delete and block cookies, please see our Which cookies we use page.

Click on the button below to accept the use of cookies on this website (this will prevent the dialogue box from appearing on future visits)